Skip to main content

Eating Disorder Diagnostic Scale

Eating Disorder Diagnostic Scale (EDDS)

Stice, Telch, & Rizvi, 2000)

The EDDS is a 22-item self-report measure assessing symptoms of anorexia nervosa (AN), bulimia nervosa (BN), and binge eating disorder (BED) in adults.  The EDDS can be used as a screening tool a diagnostic tool, and to monitor symptom changes over time. The EDDS was developed with a population partially of adolescents and does not include a separate adolescent version. Sample items include, “Have you felt fat?” and “Has your weight influenced how you think about (judge) yourself as a person?”  Items are rated on a variety of scales including zero (“not at all”) to six (“extreme”) for items about feelings related to gaining weight, “yes” or “no” questions for items related to different eating disorders experiences, frequency ratings for items related to average eating behaviours, and questions related to the physical symptoms of eating disorders. Items encompass the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition criteria (DSM-IV, American Psychiatric Association, 1994) for all three disorders, and were adapted from the following valid structured interviews: Eating Disorder Examination and the eating disorder section of the Structured Clinical Interview for DSM Disorders. The EDDS demonstrates excellent internal consistency (α = .91) and adequate test-retest reliability over a period of one week (κ = .87). It also demonstrates construct validity by convergent mean differences of EDDS identified groups across validated measures Yale-Brown-Cornell Eating Disorder Scale, Three-Factor Eating Questionnaire, and against control groups. In addition, the EDDS demonstrates criterion validity between study interview diagnosis with the EDE and SCID, and EDDS diagnostic scores.

The measure is available online

(Stice, Hayward, Cameron, Killen, & Taylor, 2000), (Stice et al., 2000) (Stunkard & Messick, 1985) (EDE; Mazure, Halmi, Sunday, Romano, & Einhorn 1994) Stice et al., 2000   (Stice et al., 2000) (Stice, Fisher, & Martinez, 2004) (EDE, Fairbum & Cooper, 1993) (SCID; Spitzer, Williams, Gibbon, & First, 1990; Stice et al., 2000)


Popular posts from this blog

ADVOKATE: A Tool for Assessment of Eyewitness Evidence

ADVOCATE: A Tool for Assessment of Eyewitness Evidence It is a tool designed to assess the eyewitness evidence that how much it is reliable. It requires the user to respond to several statements/questions. Forensic psychologist, police or investigative officer can do it. The mnemonic ADVOKATE stands for: A = amount of time under observation (event and act) D = distance from suspect V = visibility (night-day, lighting) O = obstruction to the view of the witness K = known or seen before when and where (suspect) A = any special reason for remembering the subject T = time-lapse (how long has it been since witness saw suspect) E = error or material discrepancy between the description given first or any subsequent accounts by a witness.  Working with suspects (

Diagnostic test for catatonia, the lorazepam challenge test

Benzodiazepines are the mainstay of the treatment of catatonia and are also helpful as a diagnostic probe. A positive Lorazepam Challenge Test validates the diagnosis of catatonia. After we examine the patient for signs of catatonia, 1 or 2 mg of lorazepam is administered intravenously. After 5 minutes, the patient is re-examined. If there has been no change, a second dose is given, and the patient is again reassessed (46, 78). A positive response is a marked reduction (e.g., at least 50%) of catatonic signs and symptoms, as measured with a standardized rating scale. Favorable responses usually occur within 10 min (46). If lorazepam is given intramuscularly or per os, the interval for the second dose should be longer: 15′ and 30′, respectively. Many clinicians will share the experience that a “lorazepam test” not only confirms the diagnosis of catatonia but that it also makes the underlying psychopathology apparent “by permitting mute patients to speak” (79). Analogous to the lorazepa

Classification of Depression According to the ICD-10

A first depressive episode, duration at least15 days →depressive episode (F32)  A first depressive episode, severe and rapid onset, duration less than 15 days →still depressive episode (F32) A depressive episode can be mild (2 core symptoms, 2 other symptoms from the list) (32.0) moderate (2 core symptoms, 3 or preferably 4 other symptoms) (32.1) Severe (3 core symptoms, 4 other symptoms) without psychotic symptoms (32.2) (no delusion, hallucination or stupor) Severe with psychotic symptoms (above plus either delusions, hallucinations or stupor) (F32.3) Delusions can be mood-congruent or incongruent (neutral delusions e.g. delusions of reference are considered mood incongruent. None of them count towards schizoaffective disorder unless one of the first-rank)  A mild and moderate depressive episode can be  with somatic syndrome (four or more somatic symptoms, or three very severe somatic symptoms) without somatic syndrome (three or less somatic symptoms, not severe)  A severe depressi